Researchers working on the treatment of new coronavirus monoclonal antibodies have found an antibody in SARS survivors that neutralises SARS-CoV-2 and prevents COVID-19,media reported. The SARS antibody can be used in antibody combination drugs to prevent new viruses from attaching to cells and to enhance the immune response.
We’ve seen more and more reports detailing a variety of monoclonal antibody drugs, and several of these drugs are already being developed in China, South Korea and the United States. The latest study details an unusual but exciting finding: Researchers have found that antibodies in a SARS recovery patient can be used to suppress SARS-CoV-2. SARS is another coronavirus that infected 8,422 people worldwide in 2003, 919 of them.
In a new study published in the journal Nature, researchers isolated an antibody called S309 from a SARS healer. The study was carried out by doctors from the University of Washington, the Pasteur Institute in France, the University of Ticino in Switzerland and Vir Biotechnology. Vir is one of the U.S. companies currently seeking to develop COVID-19 monoclonal antibodies.
S309 antibodies found in the healer’s blood show edify strong binding to the New Coronary Virus’s S protein, a key viral component of SARS and SARS-CoV-2, which allows both viruses to attach to cells and invade cells. Without this process, the virus cannot enter the cell for self-replication.
Laboratory experiments have shown that S309 can bind itself to the S protein, but it needs to be tested in humans to see if the antibody is effective and safe. S309 is just one of 25 SARS monoclonal antibodies found in a patient’s blood, including samples taken in 2004 and 2013.
The researchers determined that S309 is the most effective SARS neutralizing antibody that can block the new coronavirus, but the researchers say it may bind to other SARS antibodies that are less active against SARS-CoV-2 to form an antibody combination that provides additional protection.
In a separate announcement, Vir said the company, in partnership with GlaxoSmithKline, will use two genetically engineered versions of the drug with S309 antibodies in clinical trials. These two drugs are called VIR-7831 and VIR-7832. According to the company, the former should have an extended half-life, while the latter should have a longer half-life and should function as a T-cell vaccine.
“It is important to note that we believe that S309 is likely to cover the entire associated coronavirus family, suggesting that even if SARS-CoV-2 continues to evolve, it could be quite challenging for the medium-to-moderate activity of S309,” Vir’s chief scientific officer, Herbert Virgin, said in a statement. “Furthermore, S309 exhibits powerful effecton function in vitro, potentially involving antibodies and recruiting other parts of the immune system to kill infected cells.” We have seen in other animal models of respiratory infections that the effecton function can significantly increase the activity of antibodies that have been effectively neutralised.